The choice of an antibacterial drug for urinary infections treatment in children


  • A.Ye. Abaturov State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine
  • A.А. Nikulinа State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine



urinary tract infections, children, third generation cephalosporins, cefixime, review


Infections of the urinary system in childhood take the second place in the frequency of visits for primary medical care. Escherichia coli is the most causative agent of community-acquired forms of infections of the urinary system, which, as a rule, are uncomplicated and are more often diagnosed in girls after three months of age. Klebsiella pneumoniae prevails in nosocomial forms of urinary tract infections, characterized by a complicated course and more often diagnosed in boys up to three months of age. One of the causes of repeated episodes of urinary tract infections is the formation of antibiotic resistance due to the action of β-lactamases of microorganisms on the most commonly used antibacterial drugs of the aminopenicillin group. The literature review substantiates the antibiotic choice for the treatment of urinary infections in children, taking into account the clinical efficacy, safety and sensitivity of the main uropathogens. The results of the randomized clinical trials on the efficacy and safety of the use of the third generation cephalosporin — cefixime in children with urinary tract infections are summarized. Particular attention is paid to maintaining bacterial sensitivity at a level of over 90 % to the action of cefixime in Esche­richia coli and Klebsiella pneumoniae, and high compliance with the possibility of a single daily oral administration as an independent therapy on an outpatient basis and the possibility of switching from parenteral use of the third generation cephalosporins to a less invasive, especially in children, oral method.

Author Biographies

A.Ye. Abaturov, State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine

MD, PhD, Professor, Head of the Department of pediatrics 1 and medical genetics

A.А. Nikulinа, State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine

PhD, Assistant at the Department of pediatrics 1 and medical genetics



Abaturov AE, Gerasimenko ON, Agafonova EA, Vysochina IL, Krivusha EL, Nikulina AA. Early diagnosis and antibiotic therapy of urinary tract infections in children. Zdorov`e rebenka. 2012;(37):99-104. (in Russian).

Abaturov A. New Preparations of Cephalosporins Recommended for Treatment of Nosocomial Pneumonia. Pediatrics. Eastern Europe. 2019;7(1):154-164. (in Russian).

Belov BS. Cefixime in the treatment of bacterial infections: issues of effectiveness and safety. RMJ. 2013;(3):147. (in Russian).

Cefixime. DrugBank Online Catalog. Available from:

Çoban B, Ülkü N, Kaplan H, Topal B, Erdoğan H, Baskın E. Five-year assessment of causative agents and antibiotic resistances in urinary tract infections. Turk Pediatri Ars. 2014 Jun 1;49(2):124-9. doi: 10.5152/tpa.2014.1505.

Cohen R, Raymond J, Launay E, et al. Antimicrobial treatment of urinary tract infections in children. Arch Pediatr. 2017 Dec;24(12S):S22-S25. doi: 10.1016/S0929-693X(17)30514-6.

Edoo Z, Arthur M, Hugonnet JE. Reversible inactivation of a peptidoglycan transpeptidase by a β-lactam antibiotic mediated by β-lactam-ring recyclization in the enzyme active site. Sci Rep. 2017 Aug 22;7(1):9136. doi: 10.1038/s41598-017-09341-8.

El-Jade MR, Parcina M, Schmithausen RM, et al. ESBL Detection: Comparison of a Commercially Available Chromogenic Test for Third Generation Cephalosporine Resistance and Automated Susceptibility Testing in Enterobactericeae. PLoS One. 2016 Aug 5;11(8):e0160203. doi: 10.1371/journal.pone.0160203.

European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2017: Annual report of the European antimicrobial resistance surveillance network (EARS-Net). Available from:

Fan NC, Chen HH, Chen CL, et al. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. 2014 Oct;47(5):399-405. doi: 10.1016/j.jmii.2013.05.006.

Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysis. J Infect. 2016 Dec; 73(6):547-557. doi: 10.1016/j.jinf.2016.07.014.

Gunduz S, Uludağ Altun H. Antibiotic resistance patterns of urinary tract pathogens in Turkish children. Glob Health Res Policy. 2018 Mar 16;3:10. doi: 10.1186/s41256-018-0063-1.

Hameed T, Al Nafeesah A, Chishti S, Al Shaalan M, Al Fakeeh K. Community-acquired urinary tract infections in children: Resistance patterns of uropathogens in a tertiary care center in Saudi Arabia. Int J Pediatr Adolesc Med. 2019 Jun;6(2):51-54. doi: 10.1016/j.ijpam.2019.02.010.

Strohmeier Y, Hodson EM, Willis NS, Webster AC, Craig JC. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003772.

Imran M, Shah MR, Ullah F, et al. Double-tailed acyl glycoside niosomal nanocarrier for enhanced oral bioavailability of Cefixime. Artif Cells Nanomed Biotechnol. 2017 Nov;45(7):1440-1451. doi: 10.1080/21691401.2016.1246451.

Martin D, Fougnot S, Grobost F, et al. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013. J Infect. 2016 Feb;72(2):201-6. doi: 10.1016/j.jinf.2015.11.009.

Mazzariol A, Bazaj A, Cornaglia G. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review. J Chemother. 2017 Dec;29(sup1):2-9. doi: 10.1080/1120009X.2017.1380395.

Moustafa F, Nguyen G, Mathevon T, et al. Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department. J Antimicrob Chemother. 2016 Jun;71(6):1660-4. doi: 10.1093/jac/dkw021.

Naber KG, Wagenlehner FM. Novel Antibiotics in the Treatment of Urinary Tract Infections. Eur Urol Focus. 2019 Jan;5(1):10-12. doi: 10.1016/j.euf.2018.11.012.

Niu H, Yee R, Cui P, et al. Identification and Ranking of Clinical Compounds with Activity against Log-phase Growing Uropathogenic Escherichia coli. Curr Drug Discov Technol. 2018 Aug 7. doi: 10.2174/1570163815666180808115501.

O'Kelly F, Kavanagh S, Manecksha R, Thornhill J, Fennell JP. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland. BMC Infect Dis. 2016 Nov 3;16(1):620. doi: 10.1186 / s12879-016-1797-3.

Pistiki A, Tsaganos T, Galani I, Giamarellos-Bourboulis EJ. In Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections. Infect Dis Ther. 2015 Dec;4(4):425-32. doi: 10.1007/s40121-015-0089-3.

Robinson JL, Finlay JC, Lang ME, Bortolussi R; Canadian Paediatric Society, Infectious Diseases and Immunization Committee, Community Paediatrics Committee. Urinary tract infections in infants and children: Diagnosis and management. Paediatr Child Health. 2014 Jun;19(6):315-25. doi: 10.1093/pch/19.6.315.

Wang H, Huang H, Cao J, Chui D, Xiao Sh. Mass Spectral Profile for Rapid Differentiating Beta-Lactams from Their Ring-Opened Impurities. Biomed Res Int. 2015; 2015: 697958. doi: 10.1155/2015/697958.

Williams GJ, Craig JC, Carapetis JR. Preventing urinary tract infections in early childhood. Adv Exp Med Biol. 2013; 764:211-8. doi: 10.1007/978-1-4614-4726-9_18.

Williams GJ, Wei L, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD001534. doi: 10.1002/14651858.CD001534.pub3.





To Help the Pediatrician